Search research articles
Contact Us
Filters
Showing results (321-330 of 347) with videos related to
Page
of 35
Sort By:
Cancer Science
|
October 11, 2018
Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
Shaoxuan Hu, Yuqin Song, Xiuhua Sun, et al.
Cancer Communications (London, England)
|
June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study
Xuezhi Hao, Lin Wang, Yanrong Hao, et al.
Cancer Pathogenesis and Therapy
|
July 23, 2025
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
Yuankai Shi, Minghong Bi, Qingshan Li, et al.
BMC Medicine
|
April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
The Lancet. Respiratory Medicine
|
September 12, 2024
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
Baohui Han, Trevor Feinstein, Yuankai Shi, et al.
The Lancet. Oncology
|
April 13, 2021
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J Matasar, Marcelo Capra, Muhit Özcan, et al.
BMC Medicine
|
February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
The Lancet. Oncology
|
August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi, Li Zhang, Xiaoqing Liu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
Jianhua Chang, Yi-Long Wu, Shun Lu, et al.
Hematological Oncology
|
July 20, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial
Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 347) with videos related to
Sort By:
Page
of 35
Cancer Science
|
October 11, 2018
Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
Shaoxuan Hu, Yuqin Song, Xiuhua Sun, et al.
Cancer Communications (London, England)
|
June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study
Xuezhi Hao, Lin Wang, Yanrong Hao, et al.
Cancer Pathogenesis and Therapy
|
July 23, 2025
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
Yuankai Shi, Minghong Bi, Qingshan Li, et al.
BMC Medicine
|
April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
The Lancet. Respiratory Medicine
|
September 12, 2024
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
Baohui Han, Trevor Feinstein, Yuankai Shi, et al.
The Lancet. Oncology
|
April 13, 2021
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J Matasar, Marcelo Capra, Muhit Özcan, et al.
BMC Medicine
|
February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
The Lancet. Oncology
|
August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi, Li Zhang, Xiaoqing Liu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
Jianhua Chang, Yi-Long Wu, Shun Lu, et al.
Hematological Oncology
|
July 20, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial
Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, et al.
Page
of 35